Investing in Transformative Biotech Companies

The Aescap funds invest in publicly traded biotech / life sciences companies. They invest in high-growth, innovative companies that develop and market new medicines and in some cases diagnostics and medical devices. The funds comply with the Dutch Authority Financial Markets (AFM) and are managed by a broad and experienced team with a great track record. A team that has invested a significant amount of money in the Aescap funds themselves. Aescap aims to generate preferred financial returns by choosing a focused investment approach picking around 20 companies per fund. It acts as a private equity player on the stock market by being heavily involved in the companies it invests in. The name Aescap is derived from ‘Aesculapius’, the Roman god of Medicine, and ‘Capital’.


The companies in the portfolios of the Aescap biotech funds address medical needs that are not met by products available today.

We believe everybody has the right to receive the best medical care available. Aescap’s investments have a substantial positive impact on society and have already resulted in an improvement of the quality of live of millions of people worldwide.

Update via Webcast

Our presentation for existing and interested investors is currently replaced by a webcast. The next webcast will be held on December 13, 2022 at 15:00 CET.

Meet the Investment Team

The Aescap investment team, led by portfolio manager Patrick Krol, consists of experienced professionals with different backgrounds in the health care industry. Aescap aims to providing a good financial return to their investors, and in parallel contribute to improving the well-being of millions of people. The team invests in the Aescap funds themselves with over 25 million euro.

Subscribe to our Newsletter here.

    Latest news

    Aescap Genetics Newsletter Q3 2022

    From treatment of symptoms to cure. The number of genetic medicines that are so advanced in R&D that they are tested on humans has been increasing by an average of 27% per year since 2016.

    Aescap Life Sciences Newsletter Q3 2022

    Upward potential of portfolio further increased. The fund made a small positive net performance for the third quarter of 1,8%. Continuous poor market sentiment continued to depress share prices of our portfolio companies despite the present and expected future revenue and profit growth these innovative companies face.

    Aescap Life Sciences Newsletter Q2 2022

    Solid performance across portfolio. Due to a strong net performance of +13,2% since we published our NAV of mid June, the net performance of the fund for June ended at +8,8%.